This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Simon Fraser University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $596,701
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
CIHR · 2022 · Principal investigator
Development of targeted alpha therapy (TAT) radiopharmaceuticals for melanoma treatment using 213Bi, 225Ac, and 227Th labelled alpha melanocyte stimulating hormone (alphaMSH) derivatives
Principal investigators: Yang, Hua; Benard, Francois
Keywords: A-Melanocyte-Stimulating Hormone; Alpha Particle Emitting Radionuclides; Melanocortin 1 Receptor; Melenoma Treatment; Radiochemistry Development; Radiopharmaceutical Development; Targeted Radionuclide Therapy
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.